Applied Materials Today, Год журнала: 2024, Номер 38, С. 102193 - 102193
Опубликована: Апрель 17, 2024
Язык: Английский
Carbohydrate Polymers, Год журнала: 2024, Номер 345, С. 122571 - 122571
Опубликована: Авг. 5, 2024
Язык: Английский
Процитировано
8
International Journal of Pharmaceutics, Год журнала: 2024, Номер 657, С. 124182 - 124182
Опубликована: Апрель 30, 2024
Язык: Английский
Процитировано
7
Pharmaceutics, Год журнала: 2024, Номер 16(5), С. 680 - 680
Опубликована: Май 17, 2024
Lung diseases have received great attention in the past years because they contribute approximately one-third of total global mortality. Pulmonary drug delivery is regarded as one most appealing routes to treat lung diseases. It addresses numerous drawbacks linked traditional dosage forms. presents notable features, such as, for example, a non-invasive route, localized delivery, low enzymatic activity, degradation, higher patient compliance, and avoiding first-pass metabolism. Therefore, pulmonary route commonly explored delivering drugs both locally systemically. Inhalable nanocarrier powders, especially, lipid nanoparticle formulations, including solid-lipid nanostructured-lipid nanocarriers, are attracting considerable interest addressing respiratory thanks their significant advantages, deep deposition, biocompatibility, biodegradability, mucoadhesion, controlled released. Spray drying scalable, fast, commercially viable technique produce nanolipid powders. This review highlights ideal criteria inhalable spray-dried SLN NLC powders administration route. Additionally, promising inhalation devices, known dry powder inhalers (DPIs) powder-based medications, applications treating chronic conditions, considered.
Язык: Английский
Процитировано
7
Pharmaceutics, Год журнала: 2024, Номер 16(8), С. 969 - 969
Опубликована: Июль 23, 2024
Lung cancer is the leading cause of cancer-related mortality worldwide, largely due to limited efficacy anticancer drugs, which primarily attributed insufficient doses reaching lungs. Additionally, patients undergoing treatment experience severe systemic adverse effects distribution drugs non-targeted sites. In light these challenges, there has been a growing interest in pulmonary administration for lung cancer. This route allows be delivered directly lungs, resulting high local concentrations that can enhance antitumor while mitigating toxic effects. However, poses challenge overcoming mechanical, chemical, and immunological defenses respiratory tract prevent inhaled drug from properly penetrating To overcome drawbacks, use nanoparticles inhaler formulations may promising strategy. Nanoparticles assist minimizing clearance, increasing penetration into epithelium, enhancing cellular uptake. They also facilitate increased stability, promote controlled release, delivery target sites, such as tumor environment. Among them, chitosan-based demonstrate advantages over other polymeric nanocarriers their unique biological properties, including activity mucoadhesive capacity. These properties have potential when administered via route. view above, this paper provides an overview research conducted on drug-loaded incorporated devices Furthermore, article addresses emerging technologies, siRNA (small interfering RNA), context therapy. Particularly, recent studies employing are described.
Язык: Английский
Процитировано
7
Materials Today Bio, Год журнала: 2025, Номер 31, С. 101616 - 101616
Опубликована: Фев. 26, 2025
Язык: Английский
Процитировано
1
Emergent Materials, Год журнала: 2024, Номер unknown
Опубликована: Апрель 24, 2024
Язык: Английский
Процитировано
4
ACS Nano, Год журнала: 2025, Номер unknown
Опубликована: Фев. 18, 2025
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), a rapidly progressing failure condition, results in high mortality rate, especially severe cases. Numerous trials have investigated various pharmacotherapy approaches, but their effectiveness remains uncertain. Here, we present an inhaled nanoformulation of fingolimod (FTY720)-nobiletin (NOB)- poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) with good biocompatibility and sustained-release pharmacological effect. The formulation decreases the toxicity FTY720 increases bioavailability NOB since use PLGA to encapsulate at same time. In vitro, comparison treatment pure drug, demonstrated that FTY720-NOB-PLGA NPs can reduce interleukin-6 (IL-6) reactive oxygen species (ROS) release by macrophages after lipopolysaccharide (LPS) stimulation more efficiently. vivo, used inhalation tower system allowed exposure unanesthetized mice aerosolized under controlled conditions. We attenuate LPS suppressing cytokine release, such as IL-6 tumor necrosis factor-α (TNF-α). trigger pathway ALI, including nuclear factor κ-light-chain-enhancer activated B cells (NF-κB) p38 mitogen-activated protein kinase, was also efficiently inhibited. Furthermore, provided safety profile, without detrimental effects on biochemical markers function. feasibility administering noninvasively continuous monitoring developed show excellent promise for acute therapy future.
Язык: Английский
Процитировано
0
Pharmaceutics, Год журнала: 2025, Номер 17(3), С. 329 - 329
Опубликована: Март 3, 2025
Objectives: Liposomes are a promising drug carrier for inhaled delivery systems and their physical parameters could influence therapeutic efficacy significantly. This study was designed to answer the specific question of proper surface charge liposomes in pulmonary inhalation, as well synergistic anti-inflammation between drugs. Methods: In this work, series drug-loaded with different charges (from negative positive) were prepared, several vitro vivo assays, including cytotoxicity, hemolysis assay, mucus penetration lipopolysaccharide (LPS)-induced pneumonia model test, adopted evaluate biocompatibility above liposomes. Results: Compared cationic liposomes, anionic capable better good (low blood compatibility mild tissue inflammation), but poor cellular uptake by immune cells. specific, even when liposome only +2.6 mV, its cytotoxicity reached around 20% 15%, respectively. Furthermore, there no significant difference (−25.9 vs. −2.5 mV), slightly negative-charged exhibited uptake. Conclusions: Thus, (−1~−3 mV) be considering both biocompatibility. an LPS-induced mouse model, achieved anti-inflammatory compared free
Язык: Английский
Процитировано
0
International Journal of Pharmaceutics, Год журнала: 2025, Номер unknown, С. 125509 - 125509
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Advanced Drug Delivery Reviews, Год журнала: 2025, Номер unknown, С. 115575 - 115575
Опубликована: Апрель 1, 2025
Synchronisation of the suprachiasmatic nucleus (SCN) driven endogenous clock, located within central nervous system (CNS), and exogenous time cues, is essential for maintaining circadian rhythmicity, homeostasis overall wellbeing. Disordered rhythms have been associated with various conditions, inclusive neurodegenerative disorders, such as Alzheimer's disease Parkinson's disease. Traditional pharmacological approaches to dysfunction in disorders primarily focused on oral drug delivery. Oral medications often face challenges achieving necessary systemic circulation effectively bypass blood brain barrier (BBB) reach CNS, due low or variable bioavailability. Advancements non-invasive delivery methods, orally inhaled intranasal formulations, present promising alternatives targeting CNS. Orally allows rapidly achieve high through increased bioavailability fast onset action. Additionally, therapies BBB olfactory trigeminal nerve pathways directly enter This review assesses potential treat conditions. In addition, this will explore melatonin an example enhancing therapeutic outcomes by adopting formulations improve absorption target disorder more effectively.
Язык: Английский
Процитировано
0